Biotest AG: Biotest AG: Annual general meeting approves payout of dividend

PRESS RELEASE

Biotest AG: Annual general meeting approves payout of dividend

- Dividend payout of EUR 0.05 per ordinary share and EUR 0.07 per preference share

Dreieich/ Frankfurt a. M., 30 August 2017. At the annual general meeting (AGM) held on 30 August 2017 in Frankfurt/ Main, shareholders of Biotest AG approved the payment of a dividend. With 79.6 percent of the ordinary share capital represented at the meeting, a payment of EUR 0.05 per ordinary share and EUR 0.07 per preference share was resolved with a high degree of approval. The overall dividend payment will amount to EUR 2.4 million.

The annual general meeting, with 182 shareholders present, formally discharged the members of the Management Board and Supervisory Board for financial year 2016.

The full text of the speech given by the CEO of Biotest AG, Dr. Bernhard Ehmer, at the AGM is available at:
http://www.biotest.com/de/en/investor_relations/shareholders_meeting_2017.cfm

Today it was also announced that the third project - milestone of the Biotest Next Level (BNL) project was reached lst week with the successful GMP * inspection by the competent authority (Regierungspräsidium Darmstadt). A successful acceptance of the inspection is a prerequisite for a permission of the laboratory operation and thus part of the manufacturer's license. The new BNL laboratories were classified as GMP*-adequate and were released with immediate effect without restrictions.

GMP*= Good manufacturing practice

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,400 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.de

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, Munich, Stuttgart

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.